Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ya-Xin Zhao
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
ORCID:
0000-0001-5266-1562
Observed ORCID:
0000-0001-5266-1562
OpenAlex ID:
A5112442284
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
2019
·
Yi-Zhou Jiang
, Ding Ma
, et al.
·
Cancer Cell
·
1,207
PDF
HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer
2025
·
Yi Xiao
, Ying Xu
, et al.
·
Cell Metabolism
·
46
A Nomogram Predicting Lymph Node Metastasis in T1 Breast Cancer based on the Surveillance, Epidemiology, and End Results Program
2019
·
Ya-Xin Zhao
, Yi-Rong Liu
, et al.
·
Journal of Cancer
·
40
PDF
BMP4 Cross-talks With Estrogen/ERα Signaling to Regulate Adiposity and Glucose Metabolism in Females
2016
·
Shu-wen Qian
, Yan Liu
, et al.
·
EBioMedicine
·
20
PDF
Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
·
Cancer Research
·
11
Table S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Data from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Show more works
View as search
Works count:
22
Citation count:
1,321
H-index:
5
I10-index:
5
Year
Topic
Type